polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution
Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
SUFLAVE is an oral polyelectrolyte solution containing polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride. It is a bowel cleansing agent indicated for colonoscopy preparation by inducing osmotic diarrhea to evacuate the colon. This is a non-absorbed electrolyte formulation designed to cleanse the bowel without systemic electrolyte imbalance.
Product is at peak lifecycle stage post-approval with emerging Medicare utilization; commercial team likely remains small given modest Part D claims volume.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SUFLAVE currently has zero linked job openings, indicating a stable, lean commercial team post-launch. Career opportunities on this product are limited to specialized roles in market access, brand management, or field presence in gastroenterology channels.
Worked on SUFLAVE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo